Compare ACAD & NP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACAD | NP |
|---|---|---|
| Founded | 1993 | 2017 |
| Country | United States | United States |
| Employees | N/A | 60 |
| Industry | Biotechnology: Pharmaceutical Preparations | Specialty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 4.4B |
| IPO Year | 2000 | N/A |
| Metric | ACAD | NP |
|---|---|---|
| Price | $25.58 | $31.73 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 22 | 12 |
| Target Price | ★ $30.55 | $28.17 |
| AVG Volume (30 Days) | ★ 1.9M | 987.4K |
| Earning Date | 05-06-2026 | 04-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 69.12 | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $726,437,000.00 | N/A |
| Revenue This Year | $18.80 | $25.84 |
| Revenue Next Year | $11.70 | $15.80 |
| P/E Ratio | $1,311.00 | ★ N/A |
| Revenue Growth | ★ 40.45 | N/A |
| 52 Week Low | $19.69 | $14.78 |
| 52 Week High | $28.35 | $34.61 |
| Indicator | ACAD | NP |
|---|---|---|
| Relative Strength Index (RSI) | 64.96 | 57.63 |
| Support Level | $25.40 | $23.62 |
| Resistance Level | $27.79 | N/A |
| Average True Range (ATR) | 0.92 | 1.71 |
| MACD | 0.13 | 0.04 |
| Stochastic Oscillator | 67.55 | 61.75 |
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.
Neptune Insurance Holdings Inc is a high-growth, profitable, data-driven MGA that offers residential and commercial insurance products, including primary flood insurance, excess flood insurance and parametric earthquake insurance, distributed through a nationwide network of agencies in the United States. The company underwrites and administers the issuance of insurance policies on behalf of a diverse panel of insurance and reinsurance companies and does not take any balance sheet insurance risk or have claims handling responsibility relating to the policies it sells.